Androclus Therapeutics Gets Venture Funding

San Diego-based Androclus Therapeutics has raised a round of venture funding from E. de Rothschild Investment Partners and Matignon Technologies. The company is developing therapeutics targeting autoimmune and inflammatory diseases including rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. The company currently has a drug candidate, an orally administered immunomodulatory peptide for the treatment of RA, in Phase II clinical trials. More information »